These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 19692124)

  • 1. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration.
    Feng X; Xiao J; Longville B; Tan AX; Wu XN; Cooper MN; McAllister IL; Isaacs T; Palmer LJ; Constable IJ
    Ophthalmology; 2009 Oct; 116(10):1908-12.e1. PubMed ID: 19692124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment.
    Goverdhan SV; Hannan S; Newsom RB; Luff AJ; Griffiths H; Lotery AJ
    Eye (Lond); 2008 Jun; 22(6):849-54. PubMed ID: 17464302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective assessment of the Y402H variant in complement factor H, genetic variants in C-reactive protein, and risk of age-related macular degeneration.
    Schaumberg DA; Christen WG; Kozlowski P; Miller DT; Ridker PM; Zee RY
    Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2336-40. PubMed ID: 16723442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration.
    Seitsonen SP; Jarvela IE; Meri S; Tommila PV; Ranta PH; Immonen IJ
    Eur J Ophthalmol; 2007; 17(6):943-9. PubMed ID: 18050121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration.
    Kim IK; Ji F; Morrison MA; Adams S; Zhang Q; Lane AM; Capone A; Dryja TP; Ott J; Miller JW; DeAngelis MM
    Mol Vis; 2008 Aug; 14():1487-95. PubMed ID: 18704199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy.
    Brantley MA; Edelstein SL; King JM; Plotzke MR; Apte RS; Kymes SM; Shiels A
    Eye (Lond); 2009 Mar; 23(3):626-31. PubMed ID: 18292785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration.
    Tsuchihashi T; Mori K; Horie-Inoue K; Gehlbach PL; Kabasawa S; Takita H; Ueyama K; Okazaki Y; Inoue S; Awata T; Katayama S; Yoneya S
    Ophthalmology; 2011 Jan; 118(1):93-100. PubMed ID: 20678803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
    Brantley MA; Fang AM; King JM; Tewari A; Kymes SM; Shiels A
    Ophthalmology; 2007 Dec; 114(12):2168-73. PubMed ID: 18054635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel.
    Chowers I; Cohen Y; Goldenberg-Cohen N; Vicuna-Kojchen J; Lichtinger A; Weinstein O; Pollack A; Axer-Siegel R; Hemo I; Averbukh E; Banin E; Meir T; Lederman M
    Mol Vis; 2008; 14():1829-34. PubMed ID: 18852870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic predictors of response to photodynamictherapy.
    Parmeggiani F; Gemmati D; Costagliola C; Semeraro F; Perri P; D'Angelo S; Romano MR; De Nadai K; Sebastiani A; Incorvaia C
    Mol Diagn Ther; 2011 Aug; 15(4):195-210. PubMed ID: 21913742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration.
    Parmeggiani F; Costagliola C; Gemmati D; D'Angelo S; Perri P; Scapoli GL; Catozzi L; Federici F; Sebastiani A; Incorvaia C
    Pharmacogenet Genomics; 2007 Dec; 17(12):1039-46. PubMed ID: 18004208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration.
    Despriet DD; Klaver CC; Witteman JC; Bergen AA; Kardys I; de Maat MP; Boekhoorn SS; Vingerling JR; Hofman A; Oostra BA; Uitterlinden AG; Stijnen T; van Duijn CM; de Jong PT
    JAMA; 2006 Jul; 296(3):301-9. PubMed ID: 16849663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
    Chen G; Tzekov R; Li W; Jiang F; Mao S; Tong Y
    Sci Rep; 2015 Sep; 5():14517. PubMed ID: 26411831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept-source optical coherence tomography.
    Teper SJ; Nowinska A; Pilat J; Wylegala E
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():108-113. PubMed ID: 26780119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration.
    Parmeggiani F; Costagliola C; Semeraro F; Romano MR; Rinaldi M; Gallenga CE; Serino ML; Incorvaia C; D'Angelo S; De Nadai K; Dell'Omo R; Russo A; Gemmati D; Perri P
    Int J Mol Sci; 2015 Aug; 16(8):19796-811. PubMed ID: 26307969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia.
    Parmeggiani F; Gemmati D; Costagliola C; Semeraro F; D'Angelo S; Perri P; Sebastiani A; Incorvaia C
    Ophthalmology; 2010 Mar; 117(3):517-23. PubMed ID: 20044141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients.
    Lau LI; Chen SJ; Cheng CY; Yen MY; Lee FL; Lin MW; Hsu WM; Wei YH
    Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3242-6. PubMed ID: 16877387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration.
    Immonen I; Seitsonen S; Tommila P; Kangas-Kontio T; Kakko S; Savolainen ER; Savolainen MJ; Liinamaa MJ
    Ophthalmology; 2010 Jan; 117(1):103-8. PubMed ID: 19896188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein and complement factor H polymorphism interaction in advanced exudative age-related macular degeneration.
    Soheilian R; Jabbarpour Bonyadi MH; Moein H; Babanejad M; Ramezani A; Yaseri M; Soheilian M
    Int Ophthalmol; 2017 Oct; 37(5):1161-1168. PubMed ID: 27778189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.